Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$9820.00
-180.00 (-1.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $31.4B · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$359.7B
P/E
8.7x
↓EV/EBITDA
5.3x
↓ROE
23.5%
↑Gross Margin
57.8%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+39.1%
FCF CAGR
—
FCF margin
21.5%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $149.20B · net income $41.26B · FCF $32.14B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $149.20B | $149.20B | $96.04B | $69.37B | $55.47B |
| Net Income | $41.26B | $41.26B | $19.12B | $-13.88B | $-1.10B |
| EBITDA | $64.80B | $64.80B | $29.67B | $-4.39B | $5.05B |
| EPS | 1125.00 | 1125.00 | 522.00 | -381.00 | -30.00 |
| Gross Margin | 57.8% | 57.8% | 58.3% | 49.0% | 42.6% |
| Operating Margin | 40.7% | 40.7% | 35.7% | 11.1% | -6.8% |
| Net Margin | 27.7% | 27.7% | 19.9% | -20.0% | -2.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.10 | 0.13 | 0.13 |
| Cash Flow | |||||
| Free Cash Flow | $32.14B | $32.14B | $31.39B | $-17.21B | $-18.80B |
| Returns | |||||
| ROE | 23.5% | 23.5% | 14.5% | -12.5% | -0.9% |
| Valuation | |||||
| P/E | 8.73 | 8.73 | 24.04 | — | — |
| EV/EBITDA | 5.26 | 5.26 | 15.16 | — | 65.08 |
| P/B | 2.05 | 2.05 | 3.48 | 3.63 | 2.60 |
| Growth & Yield | |||||
| Revenue Growth | 55.4% | 55.4% | 38.4% | 25.1% | — |
| EPS Growth | 115.5% | 115.5% | 237.0% | -1170.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-8.2%
EPS terminal req.
$871.36
Spread vs growth
123.7%
5Y implied EPS CAGR
-1.3%
EPS terminal req.
$1054.35
Spread vs growth
116.8%
10Y implied EPS CAGR
4.2%
EPS terminal req.
$1698.04
Spread vs growth
111.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.0%
Start / end P/E
24.4x → 8.7x
EPS bridge
522.00 → 1125.00
Residual
-74.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.